奇正藏药
(002287)
| 流通市值：121.82亿 | | | 总市值：122.10亿 |
| 流通股本：5.29亿 | | | 总股本：5.30亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,471,754,788.04 | 1,009,833,674.27 | 365,098,756.48 | 2,045,152,409.09 |
| 营业收入 | 1,471,754,788.04 | 1,009,833,674.27 | 365,098,756.48 | 2,045,152,409.09 |
| 二、营业总成本 | 1,166,221,882.87 | 755,374,047.61 | 299,888,820.46 | 1,628,674,386.62 |
| 营业成本 | 270,919,592.45 | 182,875,944.63 | 68,028,674.83 | 323,314,878.11 |
| 税金及附加 | 28,084,570.42 | 21,140,550.66 | 5,733,101.07 | 34,839,602.1 |
| 销售费用 | 667,009,311.27 | 419,209,053.64 | 169,679,519.01 | 977,775,312.89 |
| 管理费用 | 116,005,635.93 | 75,681,829.6 | 34,104,822.67 | 183,889,213.93 |
| 研发费用 | 41,773,785.26 | 27,321,880.68 | 12,018,942.57 | 58,626,314.46 |
| 财务费用 | 42,428,987.54 | 29,144,788.4 | 10,323,760.31 | 50,229,065.13 |
| 其中:利息费用 | 45,334,350.84 | 30,276,430.26 | 15,934,238.46 | 63,069,765.65 |
| 其中:利息收入 | 3,123,839.62 | 1,264,588.13 | 5,667,401.37 | 13,137,410.79 |
| 加:公允价值变动收益 | 68,211,971.04 | 53,145,146.88 | 28,119,979.91 | 37,074,168.19 |
| 加:投资收益 | 10,696,306.85 | 4,982,971.34 | 10,285,742.77 | 28,779,857.94 |
| 资产处置收益 | - | - | - | 318,156.83 |
| 资产减值损失(新) | -242,077.45 | -87,996.89 | - | -1,401,294.38 |
| 信用减值损失(新) | -266,855.2 | -493,889.15 | -62,952.26 | -1,271,636.55 |
| 其他收益 | 66,637,637.76 | 54,523,551.54 | 9,808,790.23 | 166,405,670.53 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 450,569,888.17 | 366,529,410.38 | 113,361,496.67 | 646,382,945.03 |
| 加:营业外收入 | 302,881.2 | 81,721.61 | 79,713.77 | 317,626.34 |
| 减:营业外支出 | 9,435,686.52 | 1,448,692.28 | 148,999.72 | 2,287,701.01 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 441,437,082.85 | 365,162,439.71 | 113,292,210.72 | 644,412,870.36 |
| 减:所得税费用 | 47,068,703.71 | 38,074,278.55 | 14,598,032.27 | 65,235,125.72 |
| 六、净利润 | 394,368,379.14 | 327,088,161.16 | 98,694,178.45 | 579,177,744.64 |
| 持续经营净利润 | 394,368,379.14 | 327,088,161.16 | 98,694,178.45 | 579,177,744.64 |
| 归属于母公司股东的净利润 | 393,375,922.95 | 325,685,757 | 97,460,837.34 | 581,198,850.19 |
| 少数股东损益 | 992,456.19 | 1,402,404.16 | 1,233,341.11 | -2,021,105.55 |
| (一)基本每股收益 | 0.74 | 0.61 | 0.18 | 1.1 |
| (二)稀释每股收益 | 0.74 | 0.61 | 0.18 | 1.1 |
| 八、其他综合收益 | -402,847.11 | 230,788.62 | 63,746.45 | 614,638.01 |
| 归属于母公司股东的其他综合收益 | -402,847.11 | 230,788.62 | 63,746.45 | 614,638.01 |
| 九、综合收益总额 | 393,965,532.03 | 327,318,949.78 | 98,757,924.9 | 579,792,382.65 |
| 归属于母公司股东的综合收益总额 | 392,973,075.84 | 325,916,545.62 | 97,524,583.79 | 581,813,488.2 |
| 归属于少数股东的综合收益总额 | 992,456.19 | 1,402,404.16 | 1,233,341.11 | -2,021,105.55 |
| 公告日期 | 2024-10-30 | 2024-08-24 | 2024-04-27 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |